Press Releases
Jun. 29, 2021 Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners
NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company…
Jun. 25, 2021 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
NEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Jun. 22, 2021 Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company…
Jun. 3, 2021 Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Mar. 31, 2021 Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company…
Mar. 29, 2021 Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology
NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »
Mar. 24, 2021 Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and… Read more »
Mar. 22, 2021 Bioasis Technologies Inc. Announces Warrant Extension and Repricing
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ?™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers… Read more »
Mar. 8, 2021 Bioasis to Attend and Present at Upcoming Investor and Industry Conferences
NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »
Feb. 10, 2021 Bioasis Announces Shares for Debt Transaction
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers… Read more »